Drug Trial Radar · NCT07017179
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
16
Actual
Start
May 20, 2025
Primary completion
Oct 23, 2026
Study completion Oct 23, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.
Conditions
- Obesity/Overweight
Interventions
AZD6234Drug
Participants will receive a subcutaneous injection weekly
PlaceboDrug
Participants will receive a subcutaneous injection weekly.
AZD9550Drug
Participants will receive a subcutaneous injection weekly
PloceboDrug
Participants will receive a subcutaneous injection weekly
AZD6234 in combination with AZD9550Drug
Participants will receive a subcutaneous injection weekly
PlaceboDrug
Participants will receive a subcutaneous injection weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 1).Time frame: From baseline to Day 141
- Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 2).Time frame: From baseline to Day 225
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Jinan, China
Research Site
Nanjing, China
Research Site
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.